Loading...

Genertec Universal Medical Group

SEHK:2666
Snowflake Description

Good value with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2666
SEHK
HK$10B
Market Cap
  1. Home
  2. HK
  3. Healthcare
Company description

Genertec Universal Medical Group Company Limited provides integrated healthcare services with integration of capital, technology, equipment, specialists, management, and training resources to hospital customers in Mainland China. The last earnings update was 125 days ago. More info.


Add to Portfolio Compare Print
2666 Share Price and Events
7 Day Returns
-0.7%
SEHK:2666
2.5%
HK Healthcare
1.6%
HK Market
1 Year Returns
-18.1%
SEHK:2666
-16.2%
HK Healthcare
-19%
HK Market
2666 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Genertec Universal Medical Group (2666) -0.7% 7% 1.4% -18.1% 11.6% -
HK Healthcare 2.5% 4.6% -4.7% -16.2% -4.3% 8.6%
HK Market 1.6% 4.5% 3.8% -19% 30.7% 10.1%
1 Year Return vs Industry and Market
  • 2666 underperformed the Healthcare industry which returned -16.2% over the past year.
Price Volatility
2666
Industry
5yr Volatility vs Market

Value

 Is Genertec Universal Medical Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Genertec Universal Medical Group. This is due to cash flow or dividend data being unavailable. The share price is HK$5.98.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Genertec Universal Medical Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Genertec Universal Medical Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SEHK:2666 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in CNY CN¥0.76
SEHK:2666 Share Price ** SEHK (2019-01-18) in HKD HK$5.98
SEHK:2666 Share Price converted to CNY reporting currency Exchange rate (HKD/ CNY) 0.864 CN¥5.17
Hong Kong Healthcare Industry PE Ratio Median Figure of 19 Publicly-Listed Healthcare Companies 21.44x
Hong Kong Market PE Ratio Median Figure of 1,480 Publicly-Listed Companies 10.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Genertec Universal Medical Group.

SEHK:2666 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SEHK:2666 Share Price ÷ EPS (both in CNY)

= 5.17 ÷ 0.76

6.79x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genertec Universal Medical Group is good value based on earnings compared to the HK Healthcare industry average.
  • Genertec Universal Medical Group is good value based on earnings compared to the Hong Kong market.
Price based on expected Growth
Does Genertec Universal Medical Group's expected growth come at a high price?
Raw Data
SEHK:2666 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 6.79x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
18.2%per year
Hong Kong Healthcare Industry PEG Ratio Median Figure of 6 Publicly-Listed Healthcare Companies 1.08x
Hong Kong Market PEG Ratio Median Figure of 460 Publicly-Listed Companies 0.71x

*Line of best fit is calculated by linear regression .

SEHK:2666 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 6.79x ÷ 18.2%

0.37x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genertec Universal Medical Group is good value based on expected growth next year.
Price based on value of assets
What value do investors place on Genertec Universal Medical Group's assets?
Raw Data
SEHK:2666 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in CNY CN¥4.56
SEHK:2666 Share Price * SEHK (2019-01-18) in HKD HK$5.98
SEHK:2666 Share Price converted to CNY reporting currency Exchange rate (HKD/ CNY) 0.864 CN¥5.17
Hong Kong Healthcare Industry PB Ratio Median Figure of 34 Publicly-Listed Healthcare Companies 1.72x
Hong Kong Market PB Ratio Median Figure of 2,115 Publicly-Listed Companies 0.92x
SEHK:2666 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SEHK:2666 Share Price ÷ Book Value per Share (both in CNY)

= 5.17 ÷ 4.56

1.13x

* Primary Listing of Genertec Universal Medical Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genertec Universal Medical Group is good value based on assets compared to the HK Healthcare industry average.
X
Value checks
We assess Genertec Universal Medical Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Genertec Universal Medical Group has a total score of 4/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Genertec Universal Medical Group expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
18.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Genertec Universal Medical Group expected to grow at an attractive rate?
  • Genertec Universal Medical Group's earnings growth is expected to exceed the low risk savings rate of 2%.
Growth vs Market Checks
  • Genertec Universal Medical Group's earnings growth is expected to exceed the Hong Kong market average.
  • Genertec Universal Medical Group's revenue growth is expected to exceed the Hong Kong market average.
Annual Growth Rates Comparison
Raw Data
SEHK:2666 Future Growth Rates Data Sources
Data Point Source Value (per year)
SEHK:2666 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 18.2%
SEHK:2666 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 26.9%
Hong Kong Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 15.6%
Hong Kong Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 12.1%
Hong Kong Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Hong Kong Market Revenue Growth Rate Market Cap Weighted Average 10.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SEHK:2666 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in CNY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SEHK:2666 Future Estimates Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31 7,205 -2,713 1,971 4
2019-12-31 5,789 -2,691 1,685 5
2018-12-31 4,293 -3,018 1,373 5
SEHK:2666 Past Financials Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income *
2018-06-30 3,860 -6,667 1,305
2018-03-31 3,639 -5,870 1,227
2017-12-31 3,419 -5,072 1,149
2017-09-30 3,265 -4,400 1,105
2017-06-30 3,111 -3,729 1,062
2017-03-31 2,910 -3,055 967
2016-12-31 2,709 -2,382 872
2016-09-30 2,587 -2,577 825
2016-06-30 2,464 -2,773 778
2016-03-31 2,330 -3,613 718
2015-12-31 2,195 -4,452 659
2015-09-30 2,031 -4,702 605

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Genertec Universal Medical Group's earnings are expected to grow by 18.2% yearly, however this is not considered high growth (20% yearly).
  • Genertec Universal Medical Group's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SEHK:2666 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Genertec Universal Medical Group Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SEHK:2666 Future Estimates Data
Date (Data in CNY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31 1.15 1.26 1.03 4.00
2019-12-31 0.98 1.05 0.92 4.00
2018-12-31 0.80 0.81 0.79 4.00
SEHK:2666 Past Financials Data
Date (Data in CNY Millions) EPS *
2018-06-30 0.76
2018-03-31 0.71
2017-12-31 0.67
2017-09-30 0.64
2017-06-30 0.62
2017-03-31 0.56
2016-12-31 0.51
2016-09-30 0.48
2016-06-30 0.46
2016-03-31 0.45
2015-12-31 0.44
2015-09-30 0.46

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Genertec Universal Medical Group is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Genertec Universal Medical Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Hong Kong market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Hong Kong market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Genertec Universal Medical Group has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Genertec Universal Medical Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Genertec Universal Medical Group's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Genertec Universal Medical Group has delivered over 20% year on year earnings growth in the past 5 years.
  • Genertec Universal Medical Group's 1-year earnings growth is less than its 5-year average (22.9% vs 28.1%)
  • Genertec Universal Medical Group's earnings growth has exceeded the HK Healthcare industry average in the past year (22.9% vs -5.7%).
Earnings and Revenue History
Genertec Universal Medical Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Genertec Universal Medical Group Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SEHK:2666 Past Revenue, Cash Flow and Net Income Data
Date (Data in CNY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 3,860.04 1,305.24 663.49
2018-03-31 3,639.37 1,226.95 650.49
2017-12-31 3,418.71 1,148.66 637.49
2017-09-30 3,264.77 1,105.19 612.88
2017-06-30 3,110.82 1,061.72 588.27
2017-03-31 2,909.77 967.01 571.38
2016-12-31 2,708.72 872.31 554.48
2016-09-30 2,586.57 825.23 539.89
2016-06-30 2,464.42 778.16 525.29
2016-03-31 2,329.81 718.34 492.86
2015-12-31 2,195.20 658.53 460.42
2015-09-30 2,030.52 604.79 409.85
2015-06-30 1,865.83 551.06 359.27
2015-03-31 1,711.30 503.85 338.09
2014-12-31 1,556.76 456.64 316.91
2013-12-31 984.02 312.74 261.27
2012-12-31 887.15 266.48 221.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Genertec Universal Medical Group has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Genertec Universal Medical Group used its assets less efficiently than the HK Healthcare industry average last year based on Return on Assets.
  • Unable to establish if Genertec Universal Medical Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.
X
Past performance checks
We assess Genertec Universal Medical Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Genertec Universal Medical Group has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Genertec Universal Medical Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Genertec Universal Medical Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Genertec Universal Medical Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Genertec Universal Medical Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Genertec Universal Medical Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Genertec Universal Medical Group Company Filings, last reported 6 months ago.

SEHK:2666 Past Debt and Equity Data
Date (Data in CNY Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 7,832.87 30,955.43 1,961.20
2018-03-31 7,832.87 30,955.43 1,961.20
2017-12-31 7,468.83 26,899.54 1,755.16
2017-09-30 7,468.83 26,899.54 1,755.16
2017-06-30 6,899.07 22,070.49 615.74
2017-03-31 6,899.07 22,070.49 615.74
2016-12-31 6,574.39 19,485.46 1,280.29
2016-09-30 6,574.39 19,485.46 1,280.29
2016-06-30 6,091.63 16,614.92 1,813.02
2016-03-31 6,091.63 16,614.92 1,813.02
2015-12-31 5,881.20 15,458.35 1,865.70
2015-09-30 5,881.20 15,458.35 1,865.70
2015-06-30 2,707.41 13,784.70 607.21
2015-03-31 2,707.41 13,784.70 607.21
2014-12-31 2,427.50 11,410.03 453.57
2013-12-31 1,168.74 7,911.62 319.00
2012-12-31 856.00 3,797.29 307.98
  • Genertec Universal Medical Group's level of debt (395.2%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (578% vs 395.2% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Genertec Universal Medical Group's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Genertec Universal Medical Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Genertec Universal Medical Group has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Genertec Universal Medical Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
3.78%
Current annual income from Genertec Universal Medical Group dividends. Estimated to be 4.25% next year.
If you bought HK$2,000 of Genertec Universal Medical Group shares you are expected to receive HK$76 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Genertec Universal Medical Group's pays a higher dividend yield than the bottom 25% of dividend payers in Hong Kong (2.13%).
  • Genertec Universal Medical Group's dividend is below the markets top 25% of dividend payers in Hong Kong (5.87%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SEHK:2666 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Hong Kong Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 13 Stocks 2%
Hong Kong Market Average Dividend Yield Market Cap Weighted Average of 918 Stocks 3.7%
Hong Kong Minimum Threshold Dividend Yield 10th Percentile 1.2%
Hong Kong Bottom 25% Dividend Yield 25th Percentile 2.1%
Hong Kong Top 25% Dividend Yield 75th Percentile 5.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SEHK:2666 Future Dividends Estimate Data
Date (Data in CN¥) Dividend per Share (annual) Avg. No. Analysts
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.30 3.00
2019-12-31 0.27 4.00
2018-12-31 0.23 4.00
SEHK:2666 Past Annualized Dividends Data
Date (Data in CN¥) Dividend per share (annual) Avg. Yield (%)
2018-06-05 0.195 3.944
2017-04-18 0.136 2.492
2017-03-28 0.150 2.416
2016-04-19 0.108 2.099
2016-03-29 0.108 2.183

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Genertec Universal Medical Group has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Genertec Universal Medical Group only paid a dividend in the past 3 years.
Current Payout to shareholders
What portion of Genertec Universal Medical Group's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (3.8x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be thoroughly covered by earnings (7x coverage).
X
Income/ dividend checks
We assess Genertec Universal Medical Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Genertec Universal Medical Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Genertec Universal Medical Group has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Genertec Universal Medical Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jiahong Peng
COMPENSATION CN¥3,560,000
AGE 47
TENURE AS CEO 0.2 years
CEO Bio

Ms. Jiahong Peng has been Vice Chairman and Chief Executive Officer of Genertec Universal Medical Group Company Ltd since November 30, 2018. Ms. Peng has been the Chief Financial Officer and Deputy General Manager of Genertec Universal Medical Group Company Ltd since July 2012 and has been its Executive Director since December 22, 2014. Ms. Peng is primarily responsible for financial planning and management, risk management, finance management, human resources and related administrative matters. She has been General Manager of the finance department of CU Leasing since September 2008. Ms. Peng has been Chief Financial Officer and Deputy General Manager of CU Leasing (TJ) since its incorporation in December 2014. She has over 20 years working experience in financial services and financial management, including nine years in healthcare finance services. Before joining Universal Medical Group, she served as the Manager of the finance department from August 1993 to August 2006 in CNTIC and she was mainly responsible for management of financing, fund risk, budgeting and financial reports preparation. Ms. Peng joined Universal Medical Group in August 2006 as a Deputy General Manager of the finance department of CU Leasing. She has been Director of CU Leasing since December 2014. Ms. Peng is the sole beneficial owner and sole director of Evergreen. Ms. Peng serves as Director of WHSL. WHSL and Evergreen. She graduated from the University of International Business and Economics, China with a Bachelor degree in Professional Accounting in June 1993. She also obtained an Executive Master of Business Administration (EMBA) degree from Tsinghua University, China in June 2012. She was qualified as a Senior Accountant in December 2006 by the Appraisal and Approval Committee for Professional & Technical Qualification of GT-PRC.

CEO Compensation
  • Jiahong's compensation has been consistent with company performance over the past year.
  • Jiahong's remuneration is about average for companies of similar size in Hong Kong.
Management Team

Jiahong Peng

TITLE
Vice Chairman
COMPENSATION
CN¥4M
AGE
47
TENURE
0.2 yrs

Gang Yu

TITLE
Executive Director
AGE
55

Patsy Cheng

TITLE
Company Secretary
AGE
60
TENURE
3.8 yrs
Board of Directors Tenure

Average tenure and age of the Genertec Universal Medical Group board of directors in years:

3.6
Average Tenure
54.5
Average Age
  • The tenure for the Genertec Universal Medical Group board of directors is about average.
Board of Directors

Yichen Zhang

TITLE
Chairman
AGE
54

Jiahong Peng

TITLE
Vice Chairman
COMPENSATION
CN¥4M
AGE
47
TENURE
0.2 yrs

Gang Yu

TITLE
Executive Director
AGE
55
TENURE
0.2 yrs

Guang Su

TITLE
Non-Executive Director
AGE
37
TENURE
4.1 yrs

Yinquan Li

TITLE
Independent Non-Executive Director
COMPENSATION
CN¥181K
AGE
63
TENURE
3.6 yrs

Siu Lui Chow

TITLE
Independent Non-Executive Director
COMPENSATION
CN¥181K
AGE
58
TENURE
3.6 yrs

Xiaoping Liu

TITLE
Non-Executive Director
AGE
62
TENURE
6.6 yrs

Zhiyong Liu

TITLE
Non-Executive Director
AGE
47
TENURE
6.8 yrs

Wei Kong

TITLE
Independent Non-Executive Director
COMPENSATION
CN¥181K
AGE
46
TENURE
3.6 yrs

Demin Han

TITLE
Independent Non-Executive Director
COMPENSATION
CN¥181K
AGE
66
TENURE
2.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (HK$) Value (HK$)
10. Jul 18 Buy Weiping Guo Individual 05. Jul 18 05. Jul 18 200,000 HK$5.97 HK$1,193,199
09. Jul 18 Buy Weiping Guo Individual 04. Jul 18 04. Jul 18 150,000 HK$6.03 HK$904,995
06. Jul 18 Buy Weiping Guo Individual 03. Jul 18 03. Jul 18 100,000 HK$6.04 HK$603,500
05. Jul 18 Buy Weiping Guo Individual 29. Jun 18 29. Jun 18 38,500 HK$6.05 HK$232,925
04. Jul 18 Buy Weiping Guo Individual 28. Jun 18 28. Jun 18 219,000 HK$6.00 HK$1,313,628
03. Jul 18 Buy Weiping Guo Individual 27. Jun 18 27. Jun 18 300,000 HK$6.12 HK$1,835,789
25. Jun 18 Buy Weiping Guo Individual 20. Jun 18 20. Jun 18 206,000 HK$6.35 HK$1,307,502
21. Jun 18 Buy Weiping Guo Individual 15. Jun 18 15. Jun 18 250,000 HK$6.57 HK$1,642,351
29. Jun 18 Buy Weiping Guo Individual 26. Jun 18 26. Jun 18 600,000 HK$6.18 HK$3,709,981
26. Jun 18 Buy Weiping Guo Individual 21. Jun 18 21. Jun 18 400,000 HK$6.37 HK$2,549,999
22. Jun 18 Buy Weiping Guo Individual 19. Jun 18 19. Jun 18 480,000 HK$6.38 HK$3,060,288
04. Apr 18 Buy Weiping Guo Individual 28. Mar 18 28. Mar 18 1,000,000 HK$6.92 HK$6,920,003
08. Mar 18 Buy Brandes Investment Partners, L.P. Company 06. Mar 18 06. Mar 18 2,076,000 HK$6.33 HK$13,141,079
X
Management checks
We assess Genertec Universal Medical Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Genertec Universal Medical Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Genertec Universal Medical Group Company Limited (HKG:2666) Delivered A Better ROE Than Its Industry

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … To keep the lesson grounded in practicality, we'll use ROE to better understand Genertec Universal Medical Group Company Limited (HKG:2666). … Over the last twelve months Genertec Universal Medical Group has recorded a ROE of 17%.

Simply Wall St -

Is Genertec Universal Medical Group Company Limited's (HKG:2666) P/E Ratio Really That Good?

We'll look at Genertec Universal Medical Group Company Limited's (HKG:2666) P/E ratio and reflect on what it tells us about the company's share price. … Based on the last twelve months, Genertec Universal Medical Group's P/E ratio is 6.77. … How Do I Calculate Genertec Universal Medical Group's Price To Earnings Ratio

Simply Wall St -

How Much Are Genertec Universal Medical Group Company Limited (HKG:2666) Insiders Spending On Buying Shares?

So before you buy or sell Genertec Universal Medical Group Company Limited (HKG:2666), you may well want to know whether insiders have been buying or selling. … Check out our latest analysis for Genertec Universal Medical Group. … Genertec Universal Medical Group Insider Transactions Over The Last Year.

Simply Wall St -

Do Institutions Own Shares In Genertec Universal Medical Group Company Limited (HKG:2666)?

The big shareholder groups in Genertec Universal Medical Group Company Limited (HKG:2666) have power over the company. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Genertec Universal Medical Group has a market capitalization of HK$11b, so we would expect some institutional investors to have noticed the stock.

Simply Wall St -

Should You Worry About Genertec Universal Medical Group Company Limited's (HKG:2666) CEO Pay Check?

Weiping Guo became the CEO of Genertec Universal Medical Group Company Limited (HKG:2666) in 2015. … View our latest analysis for Genertec Universal Medical Group? … At the time of writing our data says that Genertec Universal Medical Group Company Limited has a market cap of HK$10.5b, and is paying total annual CEO compensation of CN¥4m.

Simply Wall St -

Genertec Universal Medical Group Company Limited (HKG:2666): A Fundamentally Attractive Investment

Attractive stocks have exceptional fundamentals. … In the case of Genertec Universal Medical Group Company Limited (HKG:2666), there's. … is a company with

Simply Wall St -

Does Genertec Universal Medical Group Company Limited's (HKG:2666) PE Ratio Signal A Buying Opportunity?

and want to start learning about core concepts of fundamental analysis on practical examples from today's market. … Genertec Universal Medical Group Company Limited (HKG:2666) trades with a trailing P/E of 7.1x, which is lower than the industry average of 33x. … View our latest analysis for Genertec Universal Medical Group

Simply Wall St -

Should You Be Happy With Universal Medical Financial & Technical Advisory Services Company Limited's (HKG:2666) Performance Lately?

For investors with a long-term horizon, examining earnings trend over time and against industry peers is more insightful than looking at an earnings announcement in one point in time. … Investors may find my commentary, albeit very high-level and brief, on Universal Medical Financial & Technical Advisory Services Company Limited (HKG:2666) useful as an attempt to give more color around how Universal Medical Financial & Technical Advisory Services is currently performing. … View our latest analysis for Universal Medical Financial & Technical Advisory Services.

Simply Wall St -

How Does Universal Medical Financial & Technical Advisory Services Company Limited (HKG:2666) Compare To The Healthcare Sector?

which faces key trends such as rising demand fuelled by an aging population and the growing prevalence of chronic diseases … the challenges facing the healthcare providers in particular, are complex and interrelated … A focus towards more collaborative and data-driven care models, which address behavioural and physical health of chronic illness or aging patients, may help improve patient outcomes and lowered costs.

Simply Wall St -

Why You Should Look Beyond Universal Medical Financial & Technical Advisory Services Company Limited's (HKG:2666) Growth

Universal Medical Financial & Technical Advisory Services Company Limited (HKG:2666) continues to post impressive revenue growth and its prospects have never been brighter. … I will conduct a high level fundamental analysis on the company by looking at its past financials and growth prospects moving forward. … Universal Medical Financial & Technical Advisory Services Company Limited provides integrated healthcare services with integration of capital, technology, equipment, specialists, management, and training resources to hospital customers in Mainland China.

Simply Wall St -

Company Info

Map
Description

Genertec Universal Medical Group Company Limited provides integrated healthcare services with integration of capital, technology, equipment, specialists, management, and training resources to hospital customers in Mainland China. It offers healthcare financial services; hospital investment, construction, and management services; and medical technology services with a focus on clinical department upgrade and hospital digitalization services. The company also provides industry, equipment, and financing advisory services, as well as finance leasing and property management services. In addition, Universal Medical Financial & Technical Advisory Services Company Limited sells medical related goods. It serves hospitals and other healthcare institutions, and educational and other public institutions. The company was formerly known as Universal Medical Financial & Technical Advisory Services Company Limited and changed its name to Genertec Universal Medical Group Company Limited in July 2018. Genertec Universal Medical Group Company Limited was founded in 1984 and is headquartered in Beijing, China.

Details
Name: Genertec Universal Medical Group Company Limited
2666
Exchange: SEHK
Founded: 1984
HK$10,263,501,388
1,716,304,580
Website: http://www.universalmsm.com
Address: Genertec Universal Medical Group Company Limited
Zhongyi Tower,
8th Floor,
Beijing,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SEHK 2666 Domestic Shares The Stock Exchange of Hong Kong Ltd. HK HKD 08. Jul 2015
OTCPK UMTA.F Domestic Shares Pink Sheets LLC US USD 08. Jul 2015
DB 5UM Domestic Shares Deutsche Boerse AG DE EUR 08. Jul 2015
SHSC 2666 Domestic Shares Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect HK HKD 08. Jul 2015
SZSC 2666 Domestic Shares The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect HK HKD 08. Jul 2015
Number of employees
Current staff
Staff numbers
655
Genertec Universal Medical Group employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/01/20 12:54
End of day share price update: 2019/01/18 00:00
Last estimates confirmation: 2019/01/18
Last earnings filing: 2018/09/17
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.